2024/11/14 更新

お知らせ

 

写真a

カワゾエ　テツロウ
川副 徹郎
KAWAZOE TETSURO
所属
九州大学病院 消化管外科(2) 助教
医学部 医学科（併任）
職名
助教
プロフィール
消化器癌に関する基礎的、臨床的研究
外部リンク

学位

  • 博士(医学)

受賞

  • 日本外科学会　第2回優秀論文賞

    2020年4月   日本外科学会  

  • 第57回日本癌治療学会　最優秀演題賞

    2019年10月   日本癌治療学会  

論文

  • RAS mutant transverse colon cancer with multiple liver metastases achieving long-term disease-free survival with postoperative maintenance therapy with aflibercept plus FOLFIRI and four repeated radical resections: a case report

    Tanaka, Y; Nakanishi, R; Sato, S; Otake, A; Ryujin, K; Ikeda, S; Ebata, Y; Harima, T; Natsugoe, K; Yoshiyama, T; Shin, Y; Kawazoe, T; Kudo, K; Zaitsu, Y; Hisamatsu, Y; Ando, K; Nakashima, Y; Itoh, S; Oki, E; Oda, Y; Yoshizumi, T

    SURGICAL CASE REPORTS   10 ( 1 )   231   2024年10月   （ ISSN:2198-7793 ）

    　詳細を見る

  • Impact of surgical proximal and distal margins on the recurrence of resectable colon cancer: a single-center observational cohort study

    Kawazoe, T; Toyota, S; Nakanishi, R; Tajiri, H; Zaitsu, Y; Nakashima, Y; Ota, M; Oki, E; Yoshizumi, T

    SURGERY TODAY   54 ( 10 )   1248 - 1254   2024年10月   （ ISSN:0941-1291 eISSN:1436-2813 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Surgery Today  

    Purpose: Few studies have investigated the impact of the surgical proximal and distal margins on colon cancer recurrence. We conducted this study to investigate the effect of resection margins on the prognosis of resectable colon cancer. Methods: We analyzed data on 1458 patients who underwent colorectal resection in our institute between January, 2004 and March, 2020, including 579 patients with resectable colon cancer. The association between the resection margin and recurrence for each oncological status was assessed and the value of the resection length that influenced recurrence was analyzed. Results: Patients who had pT4 colon cancer with margins of more than 7 cm had a trend of fewer recurrences and longer relapse-free survival (RFS) than those with colon cancer of other stages (P = 0.033; hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.20–0.89). Multivariate analysis identified a margin of < 7 cm as an independent risk factor for RFS in patients with pT4 colon cancer (P = 0.023; HR, 2.65; 95% CI 1.013–6.17). No correlation was found between resection margins and recurrence, depending on the extent of lymph node metastasis and tumor location. Conclusion: A resection margin of at least 7 cm should be maintained for patients with pT4 colon cancer.

    DOI： 10.1007/s00595-024-02836-8

    Web of Science

    Scopus

    PubMed

  • 食道癌診療における高齢者のリスク評価および治療強度調整の試み

    中島 雄一郎, 西嶋 智洋, 夏越 啓多, 進 勇輝, 川副 徹郎, 田尻 裕匡, 太田 光彦, 沖 英次, 木村 和恵, 山本 学, 森田 勝, 藤 也寸志, 吉住 朋晴

    日本気管食道科学会会報   75 ( 2 )   144 - 144   2024年4月   （ ISSN:00290645 eISSN:18806848 ）

    　詳細を見る

    記述言語：日本語   出版者・発行元：特定非営利活動法人 日本気管食道科学会  

    DOI： 10.2468/jbes.75.144

    CiNii Research

  • Neoadjuvant Chemotherapy in Patients With T4b or Obstructive Colon Cancer: A Single Center Retrospective Cohort Study

    Ebata, Y; Nakanishi, R; Tanaka, Y; Kawazoe, T; Tajiri, H; Zaitsu, Y; Nakashima, Y; Ota, M; Oki, E; Yoshizumi, T

    ANTICANCER RESEARCH   44 ( 3 )   1281 - 1287   2024年3月   （ ISSN:0250-7005 eISSN:1791-7530 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Anticancer Research  

    Background/Aim: The efficacy of neoadjuvant chemotherapy (NAC) for colon cancer remains unestablished. This study aimed to investigate the outcomes of NAC in patients with locally advanced T4b or obstructive T4a colon cancers (LACC). Patients and Methods: Data of patients with LACC who underwent colon surgery between 2010 and 2022 after NAC at our institution were retrospectively reviewed. Patient characteristics, surgical outcomes, tumor features, and prognosis were analyzed. Results: Among 800 patients with LACC who underwent radical resection, 11 received NAC because of cT4b or cT4a with mechanical obstruction. NAC, administered as a doublet regimen, had a median duration of three months, without grade ≥3 adverse events. R0 resection was achieved in all patients and downstaging was observed in eight patients. One patient developed a postoperative abdominal abscess, and adjuvant chemotherapy was administered to eight patients. Four patients experienced recurrence: liver metastasis in two, and local recurrence in two. Among these, three patients underwent resection of recurrent tumors. Median follow-up was 30 months. Conclusion: NAC is feasible for T4b or obstructive T4a colon cancer and may be a treatment option for LACC. Further large-scale studies are required to confirm the efficacy of NAC in these patients.

    DOI： 10.21873/anticanres.16923

    Web of Science

    Scopus

    PubMed

  • Preoperative Hemoglobin Level as Predictor of the Development of High-output Stoma in Rectal Cancer Surgery 査読 国際誌

    Tetsuro Kawazoe, Kippei Ohgaki, Yoshihiko Fujinaka, Huanlin Wang, Kazutoyo Morita, Ryota Nakanishi, Yoichi Ikeda

    Cancer Diagnosis and Prognosis   3 ( 6 )   667 - 672   2023年11月

    　詳細を見る

    記述言語：日本語   掲載種別：研究論文（学術雑誌）  

    DOI： doi: 10.21873/cdp.10270.

  • Preoperative Hemoglobin Level as Predictor of the Development of High-output Stoma in Rectal Cancer Surgery.

    Kawazoe T, Ohgaki K, Fujinaka Y, Wang H, Morita K, Nakanishi R, Ikeda Y

    Cancer diagnosis & prognosis   3 ( 6 )   667 - 672   2023年11月

    　詳細を見る

    記述言語：英語  

    DOI： 10.21873/cdp.10270

    PubMed

  • Successful Treatment of Refractory Enterocutaneous Fistula After Esophagectomy Using Soft Coagulation by an Endoscopic and Percutaneous Approach: A Case Report

    Ito S., Ohgaki K., Kawazoe T., Wang H., Okamoto Y., Adachi E., Ikeda Y.

    Anticancer Research   43 ( 6 )   2873 - 2877   2023年6月   （ ISSN:02507005 ）

    　詳細を見る

    出版者・発行元：Anticancer Research  

    Background/Aim: Anastomotic leakage (AL) is a serious complication after esophagectomy, and the refractory fistula (RF) following AL is therapeutically challenging with no optimal management strategies known. Thus, new therapeutic options are required for treating RF. Case Report: A 67-year-old man who underwent endoscopic mucosal dissection was subjected to subtotal esophagectomy and reconstruction with a gastric tube through the retrosternal route with cervical anastomosis as additional therapy. On postoperative day 5, leakage from the esophagogastric anastomosis was detected. A refractory enterocutaneous fistula (4 cm in length) developed between the esophagogastric anastomosis (the fistula opening was 1 cm approximately) and cervical skin. The RF did not heal despite the drainage of saliva, enteral nutrition, oral administration of biperiden hydrochloride for orofacial dyskinesia to rest the esophagogastric anastomosis, coagulation factor XIII transvenously, and fibrin glue injection from the opening of the fistula, probably due to difficulty in maintaining the rest of the esophagogastric anastomosis caused by orofacial dyskinesia. On postoperative day 76, soft coagulation to the fistula opening at the esophagogastric anastomosis by an endoscopic approach and to the fistula via the fistula opening at the cervical site by a percutaneous approach was performed. The post-treatment course was uneventful. The RF completely closed immediately after soft coagulation. Conclusion: Soft coagulation using endoscopic and percutaneous approaches to RF is a minimally invasive procedure and may be a useful option if the fistula opening of the anastomotic site is small and accessible endoscopically, and there are no vital organs around the fistula.

    DOI： 10.21873/anticanres.16457

    Scopus

  • Survival Benefits of Laparoscopic Gastrectomy in Elderly Patients With Gastric Cancer: Focusing on Preoperative Nutritional and Inflammatory Status

    Ito S., Ohgaki K., Kawazoe T., Sato S., Ikeda S., Kakizoe K., Wang H., Nakamura T., Maehara S., Adachi E., Ikeda Y., Maehara Y.

    Anticancer Research   43 ( 5 )   2055 - 2067   2023年5月   （ ISSN:02507005 ）

    　詳細を見る

    出版者・発行元：Anticancer Research  

    Background/Aim: Laparoscopic gastrectomy (LG) may have greater clinical benefits as a less invasive surgery for elderly patients with gastric cancer (GC). Therefore, we aimed to evaluate the survival benefit of LG in elderly patients with GC, especially focusing on preoperative comorbidities, and nutritional and inflammatory status. Patients and Methods: Data collected from 115 patients aged ≥75 years with primary GC who underwent curative gastrectomy, comprising 58 patients who underwent open gastrectomy (OG) and 57 patients who underwent LG, were retrospectively reviewed (total cohort), and 72 propensity-matched patients (matched cohort) were selected for survival analysis. The aim of the study was to determine short- and long-term outcomes, and the clinical markers to identify a population who may benefit from LG in elderly patients. Results: The complication and mortality rates as a short-term outcome in the total cohort and overall survival (OS) as a long-term outcome in the matched cohort did not differ significantly between the groups. In the total cohort, advanced tumor stage and ≥3 comorbidities were independent factors for poor prognosis in terms of OS [hazard ratio (HR)=3.73, 95% confidence interval (CI)=1.78-7.78, p<0.001 and HR=2.50, 95% CI=1.35-4.61, p<0.01, respectively]. The surgical approach was not an independent risk factor for postoperative complications (grade ≥III) and OS. In subgroup analysis of the total cohort, patients with a neutrophil-lymphocyte ratio (NLR) ≥3 in the LG group demonstrated a trend toward greater OS (HR=0.26, 95% CI=0.10-0.64, interaction p<0.05). Conclusion: LG might offer greater survival benefits than OG in frail patients such as those with high NLR.

    DOI： 10.21873/anticanres.16366

    Scopus

  • Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii

    Maehara, Y; Oki, E; Ota, M; Harimoto, N; Ando, K; Nakanishi, R; Kawazoe, T; Fujimoto, Y; Nonaka, K; Kitao, H; Iimori, M; Makino, K; Takechi, T; Sagara, T; Miyadera, K; Matsuoka, K; Tsukihara, H; Kataoka, Y; Wakasa, T; Ochiiwa, H; Kamahori, Y; Tokunaga, E; Saeki, H; Yoshizumi, T; Kakeji, Y; Shirabe, K; Baba, H; Shimada, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   28 ( 5 )   613 - 624   2023年5月   （ ISSN:1341-9625 eISSN:1437-7772 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：International Journal of Clinical Oncology  

    Prof. Setsuro Fujii achieved significant results in the field of drug discovery research in Japan. He developed nine well-known drugs: FT, UFT, S-1 and FTD/TPI are anticancer drugs, while cetraxate hydrochloride, camostat mesilate, nafamostat mesilate, gabexate mesilate and pravastatin sodium are therapeutic drugs for various other diseases. He delivered hope to patients with various diseases across the world to improve their condition. Even now, drug discovery research based on Dr. Fujii’s ideas is continuing.

    DOI： 10.1007/s10147-023-02326-w

    Web of Science

    Scopus

    PubMed

  • 高齢のステージIVB期食道扁平上皮癌患者における免疫チェックポイント阻害薬による化学療法後のコンバージョン手術の奏効　症例報告(Successful conversion surgery following chemotherapy with an immune checkpoint inhibitor in an older adult patient with stage IVB esophageal squamous cell carcinoma: a case report)

    Kawazoe Tetsuro, Ito Shuhei, Ohgaki Kippei, Fujinaka Yoshihiko, Funakoshi Hiroki, Otake Akihiko, Wang Huanlin, Morita Kazutoyo, Fushimi Fumiyoshi, Ikeda Yoichi

    Surgical Case Reports   9   1 of 7 - 7 of 7   2023年3月

    　詳細を見る

    記述言語：英語   出版者・発行元：Springer Berlin Heidelberg  

    症例は80歳女性。嚥下困難を主訴に来院した。上部消化管内視鏡検査で胸部下部食道に潰瘍性病変を認め、生検で中分化型扁平上皮癌と診断した。CTで胃周囲リンパ節に加え、鎖骨上リンパ節と傍下大静脈リンパ節の腫大を認めた。PET-CTで上記のリンパ節でFDGの異常集積を認めた。以上の所見から、ステージIVB期食道扁平上皮癌(cT3N2M1 cStageIVB)と診断し、ペムブロリズマブと標準化学療法の併用療法を開始した。レジメンは3週ごとのコースで、5-FU(800mg/m2)、シスプラチン(80mg/m2)、ペムブロリズマブ(200mg)を静注した。2コース終了後に好中球減少症が発現したため、5-FUとシスプラチンの投与量を減量した。4コース終了後に原発巣と転移巣の縮小を認め、PET-CTでFDGの異常集積は見られなかった。診断をycT2N0M0 ycStageIIに変更し、コンバージョン手術の方針となった。胸腔鏡下食道亜全摘術、リンパ節郭清術、胃管再建術を施行した。術後に腫瘍細胞の遺残を認めず、組織学的完全奏効と判定した。16日後に無事退院となった。10ヵ月後の再診で再発は見られなかった。

  • Refractory splenic bleeding from splenic angiosarcoma: A case report and literature review

    Kawazoe T., Ohgaki K., Adachi E., Ikeda Y., Fushimi F., Kakihara D.

    International Journal of Surgery Case Reports   99   2022年10月   （ ISSN:22102612 ）

    　詳細を見る

    出版者・発行元：International Journal of Surgery Case Reports  

    Introduction and importance: Atraumatic splenic rupture (ASR) is a rare state that accounts for only <1 % of splenic ruptures. One of the causes of ASR is splenic neoplasm such as angiosarcoma. The treatment strategy for ASR is still unclear given the small number of cases reported in detail. Case presentation: A 75-year-old woman presenting with abdominal pain with shock was referred to our hospital. Emergency computed tomography revealed splenic rupture, and hemodynamic stabilization was obtained by emergent vascular embolization. Rebleeding occurred 27 days after the initial treatment, and splenectomy was performed. Pathologically, ASR was diagnosed as caused by splenic angiosarcoma. Clinical discussion: ASR is a very rare disease. The etiology of ASR has been reported as neoplastic, infectious, and so on. The treatment for ASR should be decided considering the etiology of ASR, hemodynamic stability, volume of blood transfusion, patient status, severity of the splenic injury, and volume of intraperitoneal bleeding. Conclusions: We experienced a very rare case of ASR, in which diagnosis was challenging and the timing of surgery was difficult to determine. When splenic rupture has an atraumatic cause, splenectomy should be considered because of the possibility of malignancy.

    DOI： 10.1016/j.ijscr.2022.107708

    Scopus

  • Survival benefits of gastrectomy compared to conservative observation for older patients with resectable gastric cancer: a propensity score matched analysis

    Ito S., Ohgaki K., Kawazoe T., Wang H., Nakamura T., Maehara S., Adachi E., Ikeda Y., Maehara Y.

    Langenbeck's Archives of Surgery   407 ( 6 )   2281 - 2292   2022年9月   （ ISSN:14352443 ）

    　詳細を見る

    出版者・発行元：Langenbeck's Archives of Surgery  

    Purpose: Radical gastrectomy is considered the first choice of curative treatment for older patients with gastric cancer (GC). However, there is limited data on the survival benefits of gastrectomy for older patients with GC. Methods: This was a retrospective observational study where medical records of patients aged ≥ 75 years with clinically resectable primary GC, comprising 115 patients who underwent radical surgery (S group) and 33 patients who received conservative therapy (non-S group) (total cohort) and 44 propensity-matched patients (matched cohort), were reviewed. Survival and independent risk factors, including comorbidities and systemic nutritional and inflammatory statuses, were evaluated. Results: In the total cohort, the 5-year overall survival (OS) in the S group was significantly higher than that in the non-S group (53.7% vs 19.7%, P < 0.0001). In the matched cohort, the 3-year OS in the S group was significantly higher than that in the non-S group (59.4% vs 15.9%, P < 0.01). Multivariate analysis of the total cohort showed that no surgery was an independent prognostic factor for poor OS (hazard ratio (HR) 3.70, 95% confidence interval (CI) 1.91–7.20, P = 0.0001). In the S group in the total cohort, the multivariate analysis showed that renal disease (HR 2.51, 95% CI 1.23–5.12, P < 0.05) was an independent prognostic factor for poor OS. Conclusions: Gastrectomy for older patients improved the prognosis; however, careful patient selection is essential, especially among those with renal disease.

    DOI： 10.1007/s00423-022-02511-x

    Scopus

  • RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma A Large-cohort Observational Study (KSCC1307)

    Saeki, H; Jogo, T; Kawazoe, T; Kamori, T; Nakaji, Y; Zaitsu, Y; Fujiwara, M; Baba, Y; Nakamura, T; Iwata, N; Egashira, A; Nakanoko, T; Morita, M; Tanaka, Y; Kimura, Y; Shibata, T; Nakashima, Y; Emi, Y; Makiyama, A; Oki, E; Tokunaga, S; Shimokawa, M; Mori, M

    ANNALS OF SURGERY   275 ( 4 )   692 - 699   2022年4月   （ ISSN:0003-4932 eISSN:1528-1140 ）

    　詳細を見る

    記述言語：英語   出版者・発行元：Annals of Surgery  

    Objective:The aim of this study is to identify biomarkers that predict efficacy of preoperative therapy and survival for esophageal squamous cell carcinoma (ESCC).Background:It is essential to improve the accuracy of preoperative molecular diagnostics to identify specific patients who will benefit from the treatment; thus, this issue should be resolved with a large-cohort, retrospective observational study.Methods:A total of 656 patients with ESCC who received surgery after preoperative CDDP + 5-FU therapy, docetaxel + CDDP + 5-FU therapy or chemoradiotherapy (CRT) were enrolled. Immunohistochemical analysis of TP53, CDKN1A, RAD51, MutT-homolog 1, and programmed death-ligand 1 was performed with biopsy samples obtained before preoperative therapy, and expression was measured by immunohistochemistry.Results:In all therapy groups, overall survival was statistically separated by pathological effect (grade 3 > grade 2 > grade 0, 1, P < 0.0001). There was no correlation between TP53, CDKN1A, MutT-homolog 1, programmed death-ligand 1 expression, and pathological effect, whereas the proportion of positive RAD51 expression (≥50%) in cases with grade 3 was lower than that with grade 0, 1, and 2 (P = 0.022). In the CRT group, the survival of patients with RAD51-positive tumor was significantly worse than RAD51-negative expressors (P = 0.0119). Subgroup analysis of overall survival with respect to positive RAD51 expression indicated preoperative chemotherapy (CDDP + 5-FU or docetaxel + CDDP + 5-FU) was superior to CRT.Conclusions:In ESCC, positive RAD51 expression was identified as a useful biomarker to predict resistance to preoperative therapy and poor prognosis in patients who received preoperative CRT. Administration of preoperative chemotherapy may be warranted for patients with positive RAD51 expression.

    DOI： 10.1097/SLA.0000000000003975

    Web of Science

    Scopus

    PubMed

▼全件表示

講演・口頭発表等

▼全件表示

MISC

所属学協会

  • 日本外科学会

  • 日本消化器外科学会

  • 日本癌治療学会

  • 日本胃癌学会

  • 日本胸部外科学会

  • 日本食道学会

  • 日本内視鏡外科学会

  • 日本癌学会

  • 日本大腸肛門病学会

▼全件表示

共同研究・競争的資金等の研究課題

  • 食道扁平上皮癌における炎症関連シグナル活性化の分子機序とその制御

    研究課題/領域番号：2 2 K 1 6 5 2 6  2022年 - 2024年

    日本学術振興会  科学研究費助成事業  若手研究

    　 詳細を見る

    担当区分：研究代表者  資金種別：科研費

  • 食道扁平上皮癌における炎症関連シグナル伝達を標的とした新規治療法の開発

    2022年 - 2023年

    第 5 6 回 がん研究助成金

    　 詳細を見る

    資金種別：受託研究

  • 食道扁平上皮癌における慢性炎症シグナルを標的とした新規治療法の開発

    研究課題/領域番号：19J11357  2019年 - 2020年

    日本学術振興会  科学研究費助成事業  特別研究員奨励費

    　 詳細を見る

    担当区分：研究代表者  資金種別：科研費

  • 食道扁平上皮癌における慢性炎症シグナルを標的とした新規治療法の開発

    2019年 - 2020年

    日本学術振興会  特別研究員

    　 詳細を見る

    資金種別：共同研究

担当授業科目

  • 医工学

    2024年4月 - 2024年9月   前期

  • 消化管・腹膜

    2024年4月 - 2024年9月   前期

専門診療領域

  • 生物系／医歯薬学／外科系臨床医学／消化管外科学

臨床医資格

  • 専門医

    日本外科学会

  • 専門医

    日本消化器外科学会

医師免許取得年

  • 2014年